Robert Naismith, MD
Urology · Corpus Christi, TXNPI 1013903624
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,784 of the $4,086 with a category attached, or 68.1%. 20 manufacturers reported payments, led by Neotract Inc. at 34.3% of the total. Reporting peaked in 2020 at $1,606 and has fallen 75.4% since, to $395 in 2025. That places this record below the midpoint for urology clinicians in TX, where the typical reported total is $3,394.
Across 147 payments — averaging $27.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$1K
- Astellas Pharma US Inc$780
- Sumitomo Pharma America, Inc.$491
- AbbVie$428
- Myovant Sciences Inc.$255
- Medtronic$116
- plus $614 from 14 others
Across 3 payments — averaging $51,726 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$155K
What the payments were for
- Travel & lodging$1,22830%
- Food & beverage$2,78468%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 7 | $1,403 |
| Astellas Pharma US Inc | 58 | $780 |
| Sumitomo Pharma America, Inc. | 21 | $491 |
| AbbVie(2 entities) | 23 | $428 |
| Myovant Sciences Inc. | 12 | $255 |
| Medtronic | 2 | $116 |
| Boston Scientific | 3 | $99 |
| Agiliti Surgical, Inc. | 1 | $97 |
| Urovant Sciences Inc | 3 | $64 |
| Merck | 2 | $58 |
| Johnson & Johnson | 4 | $53 |
| Novartis | 1 | $49 |
| Myriad Genetic Laboratories, Inc. | 2 | $41 |
| Urogen Pharma, Inc. | 2 | $36 |
| Dendreon Pharmaceuticals LLC | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Tolmar, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Healthtronics Stone Solutions, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,323
How this compares
$4,086 in reported general payments places this provider in the 50th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 323 | $203,786 |
| XiaflexCollagenase Clostridium Hist. | 14 | $196,811 |
| OrgovyxRelugolix | 36 | $92,940 |
| GemtesaVibegron | 59 | $32,973 |
| Mirabegron ErMirabegron | 41 | $22,472 |
| Trospium Chloride | 136 | $6,665 |
| Tamsulosin Hcl | 522 | $4,373 |
| ElmironPentosan Polysulfate Sodium | 12 | $4,068 |
| Methenamine Hippurate | 68 | $3,257 |
| Estradiol | 37 | $2,494 |
| Solifenacin Succinate | 75 | $2,111 |
| Gemcitabine Hcl | 36 | $1,939 |
| Potassium Citrate ErPotassium Citrate | 31 | $1,876 |
| Tadalafil | 14 | $1,472 |
| Finasteride | 100 | $1,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $780 | $203,786323 claims |
| Endo Pharmaceuticals Inc.Xiaflex | $13 | $196,81114 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $491 | $125,91395 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 878 urology providers in Texas.
Other urology in Corpus Christi
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
- Michael TrotterAustin$590K
- Vitaly MargulisDallas$555K
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jonathan Clavell HernandezHouston$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.